Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock Has Average Target Price of $32.83 According to Analysts

Corvus Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts give Corvus Pharmaceuticals a consensus “Moderate Buy” rating: six recommend buying, one strongly recommends buying, and one recommends selling. Their average 12-month price target is $32.83.
  • Shares opened at $10.60, below their 50-day average of $11.11 and 200-day average of $13.99. Corvus reported a quarterly loss of $0.22 per share, missing the $0.19 loss analysts expected.
  • An insider bought 3,000 shares at an average of $11.46, and insiders purchased 4,500 shares over the past 90 days. Corvus is a clinical-stage biotech developing immune-targeting medicines, including soquelitinib for T-cell lymphoma.
  • Five stocks we like better than Corvus Pharmaceuticals.

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $32.83.

Several equities analysts recently issued reports on CRVS shares. Cantor Fitzgerald restated an "overweight" rating on shares of Corvus Pharmaceuticals in a research note on Wednesday, September 16th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Corvus Pharmaceuticals in a research note on Monday, October 26th. Mizuho set a $27.00 target price on shares of Corvus Pharmaceuticals in a report on Thursday, October 29th. Wall Street Zen cut shares of Corvus Pharmaceuticals from a "sell" rating to a "strong sell" rating in a report on Saturday, November 7th. Finally, Ladenburg Thalmann & Co. Inc. upgraded shares of Corvus Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, July 30th.

Get Our Latest Research Report on CRVS

Corvus Pharmaceuticals Stock Down 0.4%

NASDAQ:CRVS opened at $10.60 on Tuesday. The business's 50 day moving average is $11.11 and its two-hundred day moving average is $13.99. Corvus Pharmaceuticals has a 52 week low of $6.39 and a 52 week high of $26.95. The company has a market cap of $894.11 million, a PE ratio of -14.93 and a beta of 1.57.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.03). As a group, sell-side analysts expect that Corvus Pharmaceuticals will post -0.81 EPS for the current fiscal year.

Insider Buying and Selling at Corvus Pharmaceuticals

In other Corvus Pharmaceuticals news, insider Jeffrey Arcara acquired 3,000 shares of the company's stock in a transaction that occurred on Wednesday, November 11th. The shares were purchased at an average price of $11.46 per share, for a total transaction of $34,380.00. Following the completion of the purchase, the insider directly owned 3,000 shares in the company, valued at $34,380. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Over the last ninety days, insiders have bought 4,500 shares of company stock worth $50,478. 19.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Corvus Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in Corvus Pharmaceuticals in the second quarter worth $106,654,000. Commodore Capital LP acquired a new position in shares of Corvus Pharmaceuticals during the first quarter valued at $33,045,000. Perceptive Advisors LLC boosted its holdings in shares of Corvus Pharmaceuticals by 231.1% during the first quarter. Perceptive Advisors LLC now owns 2,292,441 shares of the company's stock valued at $33,538,000 after acquiring an additional 1,600,000 shares during the period. Fisher Asset Management LLC acquired a new position in shares of Corvus Pharmaceuticals during the third quarter valued at $11,988,000. Finally, Bank of America Corp DE bought a new position in shares of Corvus Pharmaceuticals during the second quarter worth about $11,322,000. 46.64% of the stock is currently owned by institutional investors and hedge funds.

Corvus Pharmaceuticals Company Profile

(Get Free Report)

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines that target the immune system to treat cancer and immune-related diseases. The company is based in Burlingame, California, and its work centers on therapies in clinical development rather than marketed products. Its lead candidate, soquelitinib (also known as CPI-818), is an oral inhibitor of interleukin-2-inducible T-cell kinase, or ITK. Corvus is developing the drug for T-cell lymphoma and has also explored its potential in inflammatory and autoimmune conditions, including atopic dermatitis.

See Also

Analyst Recommendations for Corvus Pharmaceuticals (NASDAQ:CRVS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?

Before you consider Corvus Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.

While Corvus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines